We develop and translate new stem cell–based therapies for heart disease, with a focus on stromal cells derived from adipose tissue. These belong to the broader group of mesenchymal stromal cells (MSC), known for their regenerative and immunomodulatory properties.

About the centre

The Cardiology Stem Cell Centre (CSCC) at Rigshospitalet, Department of Cardiology, Copenhagen University Hospital, is dedicated to advancing regenerative therapies for cardiovascular disease. Our research aims to develop safe, effective, and clinically relevant treatments, with a special emphasis on non-ischemic heart failure.

Cell therapy

A central element of our work is adipose-derived stromal cells (ASCs), a type of MSC that can be isolated in clinically relevant quantities. ASCs have demonstrated the ability to modulate immune responses, promote tissue repair, and support regeneration. Their accessibility and immunomodulatory potential make them a particularly promising candidate for future cell therapies in cardiology.

Our research spans the entire translational pipeline, from fundamental biology to clinical application. This includes clinical trials with ASCs and other stromal cells, the development of advanced in vitro and in vivo models, immunological studies of cell–immune system interactions, and innovation in the manufacturing and quality testing of clinical-grade cell products.

What makes CSCC unique is the close integration of clinical expertise, state-of-the-art cell manufacturing, and advanced immunological research. Being embedded in a leading cardiology department ensures direct translation from laboratory findings to patient care, while our collaborations with basic scientists and GMP facilities enable both innovation and the delivery of cell products ready for clinical testing.

Projects

At present, we are conducting the project ImmunoModulatory Potential of Adipose tissue-derived stromal Cell Therapy (IMPACT), supported by the Innovation Fund Denmark with a budget of DKK 24 million. This large-scale initiative aims to refine the therapeutic potential of ASCs through integrated preclinical, immunological, and clinical research. In the past, we have completed two related Innovation Fund projects (each DKK 25 million) as well as a Horizon 2020 grant from the European Union (EUR 6 million). We collaborate nationally and internationally to accelerate the translation of new therapies into clinical use.

Vision

Our vision is to contribute new knowledge, innovative technologies, and therapeutic strategies that improve the lives of patients with heart disease, while positioning Denmark as a leading European hub for regenerative cardiology. This page also provides links to the centre’s scientific publications and to researchers affiliated with the Cardiology Stem Cell Centre.

The spin-out company Cell to Cure originated from CSCC and today operates as an independent enterprise.